{"entity":{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","aka":[],"tldr":"A letter describing severe ivermectin poisoning in a young patient with bone cancer who was also taking regorafenib, a cancer drug that shares the enzyme ivermectin is cleared by.","summary":"Europe PMC indexes this letter without an abstract, so OnCo transcribes no figures from it (Gilene paediatric case 2025). The ICONIC trial's registry entry summarises it as a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A4 (ClinicalTrials.gov NCT07487805).","asOf":"2026-09-24","links":[{"label":"Gilene paediatric case 2025","url":"https://doi.org/10.1002/pbc.31876"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40556334/"},{"label":"ClinicalTrials.gov NCT07487805","url":"https://clinicaltrials.gov/study/NCT07487805"}],"tags":[],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ivermectin","regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":["pharmacokinetics"],"trials":["nct07487805"],"people":[],"bottlenecks":["b-misinformation"],"keyPapers":[],"journals":["pediatric-blood-and-cancer"],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Fable 5.1)","editedOn":"2026-09-24","note":"Written from cached ClinicalTrials.gov v2, Europe PMC, DailyMed, Drugs@FDA and WHO eEML responses; no figure appears without its source link."},"journal":"Pediatric Blood & Cancer","year":2025,"doi":"10.1002/pbc.31876","pmid":"40556334","authors":"Gilene S, Haacker L, Rutan H, Pressey JG.","paperType":"observational","findings":["Severe neurotoxicity in a paediatric osteosarcoma patient on regorafenib, attributed to a CYP3A4 interaction, as summarised by the ICONIC registry entry."],"whatItMeans":"A reminder that ivermectin interacts with cancer drugs: the dose that a healthy adult tolerates can poison a patient whose liver enzymes are already occupied by a kinase inhibitor.","caveats":["Letter with no indexed abstract; details are taken from the ICONIC registry's summary of it."],"changedPractice":false,"participants":1},"route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/"}],"trial":[{"id":"nct07487805","kind":"trial","name":"ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2)","route":"/trials/nct07487805/"}],"bottleneck":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/"}],"journal":[{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/"}]}}